Our study evaluated a panel of breast cancer cell lines belonging to the estrogen receptor positive (ER+) or triple negative (TN) subtypes, with a particular focus on mitochondrial metabolism and ROS management systems to suggest specific metabolic vulnerabilities that could define them or be used as targets for therapy. The gene discussed is ESR1; the disease is breast carcinoma.